Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | KDM4A | O75164 | 2/20 | 0.65 |
| ▸ | KDM4B | O94953 | 2/20 | 0.65 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.65 |
| ▸ | KDM5C | P41229 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666048 | 1.00 | L3MBTL1 (0.69) | L3MBTL1NCOA1MAPTKDM4ELMNA | |
| SCHEMBL663488 | 0.95 | L3MBTL1 (0.67) | L3MBTL1NCOA1MAPTKDM4ELMNA | |
| SCHEMBL29977722 | 0.95 | L3MBTL1 (0.67) | L3MBTL1NCOA1MAPTKDM4ELMNA | |
| SCHEMBL666388 | 0.91 | SMN1; SMN2 (0.79) | L3MBTL1NCOA1MAPTLMNASMN1; SMN2 | |
| SCHEMBL662898 | 0.86 | SMN1; SMN2 (0.71) | MAPTKDM4ELMNASMN1; SMN2KDM4A | |
| SCHEMBL29978107 | 0.86 | SMN1; SMN2 (0.71) | MAPTKDM4ELMNASMN1; SMN2KDM4A | |
| SCHEMBL29978743 | 0.84 | SMN1; SMN2 (0.69) | L3MBTL1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL664119 | 0.84 | SMN1; SMN2 (0.69) | L3MBTL1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL666355 | 0.83 | SMN1; SMN2 (0.64) | L3MBTL1NCOA1MAPTKDM4ELMNA | |
| SCHEMBL29978328 | 0.83 | SMN1; SMN2 (0.64) | L3MBTL1NCOA1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | L3MBTL1 2208/4885NCOA1 853/4885MAPT 3825/4885 |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | L3MBTL1 2208/4885NCOA1 853/4885MAPT 3825/4885 |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | WNT3A, WNT1, WNT3 | L3MBTL1 2208/4885NCOA1 853/4885MAPT 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.